Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIREFLY-2 / LOGGIC: tovorafenib versus standard chemotherapy in RAF-altered pediatric low-grade glioma
MOH_2022-12-08_012227Phase 3Recruiting
- Sponsor
- Day One Biopharmaceuticals
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tovorafenib in glioma and Glioneuronal Neoplasm (2 arms), sponsored by Day One Biopharmaceuticals. Started Nov 2022; status: recruiting.
02
Drugs
tovorafenib
03
Conditions
gliomaGlioneuronal Neoplasm
Beyond the preview
Go deeper on MOH_2022-12-08_012227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-08_012227.